Abstract:BACKGROUND: The aim of this study was to analyze the changes of interleukin-6 (IL-6), C-reactive protein (CRP), blood lipids and myocardial indexes after treatment of patients with acute myocardial infarction (AMI) with intensive atorvastatin and interventional therapy, and its clinical significance. METHODS: A total of 78 patients diagnosed with AMI in our hospital from March 2016 to February 2017 were selected and divided into treatment group (N.=39) and control group (N.=39). Patients in treatment group were treated with intensive atorvastatin based on conventional therapy before and after percutaneous coronary intervention (PCI), while those in control group were treated with conventional therapy before and after PCI. The levels of serum IL-6, CRP, blood lipids (total cholesterol [TC], triglyceride [TG], high-density lipoprotein cholesterol [HDL-C] and low-density lipoprotein cholesterol [LDL-C]) and myocardial enzyme indexes (troponin T [TnT] and creatine kinase-MB [CK-MB]) at different time points were detected. The correlations among serum CRP, TC, and TnT in treatment group before treatment were detected using the linear regression analysis, and changes in serum inflammatory factors, blood lipids and myocardial enzyme indexes in treatment group before and after treatment were analyzed. RESULTS: There were no statistically significant differences in demographics and clinical data between treatment group and controls (P>0.05). There were no significant differences, either, in levels of serum IL-6 and CRP before treatment between treatment group and control group, but they were decreased after treatment, and the curative effect in treatment group was significantly superior to that in control group. The differences were statistically significant (P<0.05). There were no significant differences in serum TC, TG, HDL-C and LDL-C levels before treatment between the two study groups. TC, TG and LDL-C were significantly decreased and HDL-C was significantly increased after treatment compared to before treatment. TnT and CK-MB were significantly increased at 24 hours after treatment (P<0.05). At 1 week, TnT was still higher, whereas CK-MB has returned to normal; at 2 weeks, they were both decreased. The curative effect in the treatment group was significantly superior to that in control group. CRP (r=0.793, P<0.001) and TC (r=0.668, P<0.001) were found to be positively correlated with TnT. The levels of serum inflammatory factors and blood lipids in the treatment group before treatment and at 24 hours, 1 week, and 2 weeks showed a decreasing trend, and TnT was increased at first, and then decreased. CONCLUSIONS: The application of intensive atorvastatin for AMI patients, especially before PCI, has high safety, which can effectively reduce levels of serum inflammatory factors and blood lipids, protect myocardial cells after PCI and avoid injury.

Effects of Simvastatin on Blood Levels of Inflammatory Cytokines in Patients with Unstable Angina Post Percutaneous Coronary Intervention

The effect of simvastatin on C reactive protein in patients with coronary heart disease

Effects of Different Doses of Rosuvastatin on High-sensitivity C-reactive Protein(hs-CRP) and Interleukin-6 (IL-6) in Patients with Acute Coronary Syndrome.

The effect of simvastatin on serum cytokine levels in patients with acute myocardial infarction

The Serum Levels of High Sensitivity C-reactive Protein and Cardiac Events after Percutaneous Coronary Intervention

The Effects of Atorvastatin on Interventional Therapy in Patients with Acute Myocardial Infarction

Effect of Simvastatin on Acute Coronary Syndrome Complicated with Atrial Fibrillation

Effects of Simvastatin on Serum Matrix Metalloproteinases-9 and C-reactive Protein Levels in Patients of Coronary Heart Disease

Influence of Short-Term Treatment with Simvastatin 40 Mg on Plasma Concentration of High-Sensitivity C-reactive Protein in Patients with Unstable Angina Pectoris

Efficacy and Safety of Serial Atorvastatin Load in Chinese Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the ISCAP (intensive Statin Therapy for Chinese Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention) Randomized Controlled Trial

Effect of high dose statin pretreatment for percutaneous coronary intervention patients with acute coronary syndrome

Effects of Atorvastatin on Interleukin-1 and C-reactive Protein Levels of Patients with Acute Myocardial Infarction

Short-term Effect of Simvastatin on Serum C-reactive Protein of Hyperlipidemia Patients

Effect of preoperative intensive statin on the efficacy and inflammatory response of acute ST-segment elevation myocardial infarction after emergency percutaneous coronary intervention

Effect of Early Treatment with Atorvastatin on Serum Levels of Inflammatory Cytokines in Patients with Unstable Angina Pectoris

Effects of Atorvastatin Loading Prior to Primary Percutaneous Coronary Intervention on Endothelial Function and Inflammatory Factors in Patients with ST-segment Elevation Myocardial Infarction

Effects of different doses of atorvastatin on prevention of contrast-induced nephropathy after percutaneous coronary intervention in patients with elevated high-sensitivity C-reactive protein:a comparative study

Efficacy of High-dose Statins Pretreatment on PCI-related Inflammation and Myocardial Injury

Effects of Preoperative Loading Dose of Atorvastatin on Serum Hs-CRP and BNP Levels and Cardiac Function of Patients with STEMI Emergency PCI

The Effect of Different Statin‐Based Lipid‐Lowering Strategies on C‐Reactive Protein Levels in Patients With Stable Coronary Artery Disease

[Different Effects of Inflammation and Lipid Levels on Coronary Lesions after PCI].